The 10-second takeaway
For the quarter ended March 31 (Q1), Nektar Therapeutics whiffed on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly. GAAP loss per share expanded.
Gross margins contracted, operating margins grew, net margins dropped.
Nektar Therapeutics notched revenue of $23.0 million. The seven analysts polled by S&P Capital IQ expected a top line of $27.5 million on the same basis. GAAP reported sales were 28% higher than the prior-year quarter's $17.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.48. The seven earnings estimates compiled by S&P Capital IQ averaged -$0.43 per share. GAAP EPS were -$0.48 for Q1 versus -$0.36 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 49.3%, 220 basis points worse than the prior-year quarter. Operating margin was -197.4%, 460 basis points better than the prior-year quarter. Net margin was -239.4%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $26.6 million. On the bottom line, the average EPS estimate is -$0.45.
Next year's average estimate for revenue is $201.2 million. The average EPS estimate is -$1.08.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 195 members out of 223 rating the stock outperform, and 28 members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 39 give Nektar Therapeutics a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nektar Therapeutics is outperform, with an average price target of $12.25.
- Add Nektar Therapeutics to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.